Ascentage Pharma Group International (NASDAQ:AAPG) Receives Buy Rating from BTIG Research

Ascentage Pharma Group International (NASDAQ:AAPG)‘s stock had its “buy” rating reaffirmed by research analysts at BTIG Research in a report released on Monday,Benzinga reports. They presently have a $48.00 target price on the stock. BTIG Research’s target price points to a potential upside of 176.82% from the stock’s previous close.

Other research analysts have also issued reports about the company. Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 price objective on the stock. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. B. Riley Financial began coverage on Ascentage Pharma Group International in a report on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective on the stock. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Two analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $46.43.

Ascentage Pharma Group International Price Performance

AAPG stock opened at $17.34 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. Ascentage Pharma Group International has a 1-year low of $16.92 and a 1-year high of $48.45. The business’s 50 day simple moving average is $21.90 and its 200 day simple moving average is $24.59.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The business had revenue of $24.72 million during the quarter. As a group, analysts expect that Ascentage Pharma Group International will post -0.96 EPS for the current fiscal year.

Institutional Trading of Ascentage Pharma Group International

Several large investors have recently modified their holdings of the stock. Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International during the 3rd quarter worth $383,000. Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International during the 2nd quarter worth $391,000. UBS Group AG grew its holdings in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares in the last quarter. Finally, XY Capital Ltd grew its holdings in shares of Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares in the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.